Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
By
Jeremy Veenstra-VanderWeele
28 January 2020 | 5 min read
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
By
Jeremy Veenstra-VanderWeele
10 June 2014 | 8 min read
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
By
Paul Middlebrooks
21 October 2026 | 1 min read
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
By
Claudia López Lloreda
21 October 2026 | 9 min read
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
By
Natalia Mesa
20 October 2026 | 7 min read